About Products & Pipeline Partnering Investors & News Blog For noninfectious diarrhea in adults living with HIV/AIDS who are on ART* Mytesi® is the ONLY FDA-approved diarrhea treatment that's been studied specifically in adults with HIV/AIDS1 Important Safety Information: MYTESI® is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). MYTESI® is not indicated for the treatment of infectious diarrhea. Read More... Committed to discovering, developing and commercializing plant-based prescription medicines for urgent global health needs About Us We focus on developing novel, sustainably derived gastrointestinal products on a global basis. Our wholly-owned subsidiary, Napo Pharmaceuticals, focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Mission We are committed to identifying opportunities to develop and commercialize first-in-class, plant-based prescription medicines that leverage our broad intellectual property portfolio, deep pipeline, and extensive botanical library and address unmet medical needs for people around the globe. News & Events Click here to access the replay of Jaguar’s April 23, 2021 Napo EU business overview webcast and the interview of Lisa Conte & Josh Mailman on Innovators with Jane King Click here to view Jaguar & Napo press releases *Indication MYTESI® is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Important Safety Information about MYTESI® MYTESI® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting MYTESI®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%). Click to Read Full Prescribing Information 1 Orange Book, www.accessdata.fda.gov/scripts/cder/ob/, accessed October 2016 © Copyright 2020 Jaguar Health Contact Us | Careers | Legal Notice | Privacy Policy | Social Media Policy | Website Accessibility Feedback Email | Web Accessibility Feedback Form | Admin |

About Products & Pipeline Partnering Investors & News Blog 404 Page Not Found Oops! That page doesn't exist. © Copyright 2020 Jaguar Health Contact Us | Careers | Legal Notice | Privacy Policy | Social Media Policy | Website Accessibility Feedback Email | Web Accessibility Feedback Form | Admin |